Other News To Note
Wednesday, November 30, 2011
BioLineRx Ltd., of Jerusalem, said it received approval from Indian regulators to start the Phase II/III CLARITY trial of BL-1020, an oral GABA-enhanced antipsychotic for treating schizophrenia. Overall, the study is expected to be conducted at about 18 sites in India, 14 sites in Romania and four sites in Israel.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.